Latest / CME Outfitters Medical Education / Individualizing HIV Treatment for Diverse Populations
Transcript
- 0:00SPEAKER_01: Hello and welcome.
- 0:02SPEAKER_01: On behalf of CME Outfitters, I'd like to welcome you and thank you for joining us.
- 0:08SPEAKER_01: This activity is titled Individualizing HIV Treatment for Diverse Populations.
- 0:14SPEAKER_01: This program has been supported by an independent educational grant from Gilead Sciences Incorporated.
- 0:22SPEAKER_01: Today's activity may include discussion of products or devices that are not approved by the U.S.
- 0:28SPEAKER_01: Food and Drug Administration or other relevant regulatory authorities.
- 0:33SPEAKER_01: Faculty have been informed of their responsibility to disclose to the audience when they discuss investigational or off-label uses of products or devices.
- 0:43SPEAKER_01: Uses not approved by applicable regulatory authorities.
- 0:48SPEAKER_01: Reimbursement, public funding, and access pathways for the therapies discussed in this activity vary by country and are subject to frequent change.
- 0:58SPEAKER_01: Content reflects information available as of the activity's development date.
- 1:03SPEAKER_01: Clinicians should consult current local or national guidance to confirm local coverage and access.
- 1:10SPEAKER_01: I'm Dr.
- 1:11SPEAKER_01: Christina Madison, clinical pharmacist, founder and CEO of the Public Health Pharmacist, and Clinical Consultant for the National Clinician Consultation Center.
- 1:21SPEAKER_01: I'm pleased to join an incredible panel for this discussion.
- 1:27SPEAKER_01: They will provide their global and regional insights.
- 1:32SPEAKER_01: Dr.
- 1:33SPEAKER_01: Barber, Becker, and Solomon, would you please introduce yourself and provide a little about your background in HIV, starting with Dr.
- 1:41SPEAKER_01: Barber.
- 1:43SPEAKER_03: Hello, I'm Dr.
- 1:44SPEAKER_03: Tristan Barber.
- 1:45SPEAKER_03: I'm a consultant in HIV medicine, working at the Royal Free Hospital in London, UK, and an honorary associate professor at the Institute for Global Health at University College London.
- 1:56SPEAKER_03: I've been working in HIV now for 24 years, and in the last few years we've developed a special interest in HIV aging and frailty.
- 2:04SPEAKER_04: Hi, and I'm Linda Gelbecker.
- 2:06SPEAKER_04: Dr.
- 2:06SPEAKER_04: Linda Gelbecker, I'm a professor of medicine and infectious diseases at the Desmond Tutu HIV Centre at the University of Cape Town, but I'm also CEO of the Desmond Tutu Health Foundation here in Cape Town, South Africa.
- 2:20SPEAKER_04: I have been looking after patients living with HIV for 30 years now, but of late have become passionate about providing the best kind of primary prevention to people who are most at risk for HIV.
- 2:37SPEAKER_04: And that has been a lifelong career and one that I love to do.
- 2:44SPEAKER_04: Handing over to Dr.
- 2:45SPEAKER_04: Solomon.
- 2:47SPEAKER_02: Hi, I'm Dr.
- 2:47SPEAKER_02: Sunil Sua Solomon.
- 2:49SPEAKER_02: I'm a professor of medicine and epidemiology from the Johns Hopkins University School of Medicine.
- 2:54SPEAKER_02: I've been working in the HIV field since early 2000s, and most of my focus has been global.
- 3:01SPEAKER_02: I do some work in the US as well, but most of it has been global, and particularly around populations such as people who inject drugs, men who have sex with men, the transgender community, to try and really think about what are the special considerations we should think of when we're planning treatment or prevention for these special populations.
- 3:21SPEAKER_01: Thank you very much for those introductions.
- 3:24SPEAKER_01: As you can see, we have a fantastic panel for today.
- 3:28SPEAKER_01: To frame today's discussion, let's review our learning objectives, which is to select appropriate HIV treatment regimens for diverse patient populations based on the latest trial data, guideline recommendations, and patient preferences.
- 3:44SPEAKER_01: We are seeing broad alignment around second generation entity-based regimens, increasing use of two drug strategies and select patients, and growing discussions of where long-acting therapies fit into treatment algorithms.
- 4:01SPEAKER_01: Dr.
- 4:01SPEAKER_01: Barber, can you start by framing the guideline harmonization piece, especially the move from three drugs to two drug combinations, and where are long-acting injectables are beginning to fit?
- 4:14SPEAKER_03: Thank you so much.
- 4:15SPEAKER_03: Yes, happy to do that.
- 4:16SPEAKER_03: I think we have, as you rightly say, in recent years, seen this harmonization of US, European, WHO guidelines around second generation integraze inhibitor-based regimens, whether these are in three drug combinations or whether they're in two drug combinations increasingly.
- 4:34SPEAKER_03: And we know the reasons for that.
- 4:36SPEAKER_03: We know that second generation integraze inhibitors are very potent against HIV replication, in general, very well tolerated, and they have very little in terms of significant drug-drug interaction risk.
- 4:49SPEAKER_03: And of course, as we've seen mounting evidence for daily two-drug therapy with dolutegrave and amividine, we've also seen that come into guidelines for first-line treatment and switch in certain scenarios.
- 5:03SPEAKER_03: But we also have existing long-acting agents.
- 5:06SPEAKER_03: And we now see guidelines also recommending long-acting injectable agents in specific circumstances.
- 5:13SPEAKER_03: And we need practical interpretation of those guidelines to think about when the right person at the right time in the right place might be able to receive these agents.
- 5:22SPEAKER_03: And we know that being recommended in a guideline doesn't always mean that every treatment is available.
- 5:28SPEAKER_03: So we need some local context to interpret these guidelines and use them in our local settings.
- 5:34SPEAKER_01: Thank you very much.
- 5:36SPEAKER_01: So, Dr.
- 5:36SPEAKER_01: Specker and Solomon, from your regional perspective, how should clinicians think about the gap between what guidelines recommend and what patients can actually access?
- 5:49SPEAKER_04: Yeah, maybe I'll kick off to say that being here in Africa, we are very much dependent on what the World Health Organization's guidelines say.
- 6:00SPEAKER_04: WHO has been a bit cautious about that because we don't have as easy access to viral load monitoring or and or specifically genotype monitoring.
- 6:10SPEAKER_04: Sunil?
- 6:11SPEAKER_02: Yeah, I would just add on to what uh Linda just said, and I'm India is sort of similar.
- 6:18SPEAKER_02: So we have about 2.4 million people living with HIV, and about 1.6 million are on antiretroviral therapy.
- 6:24SPEAKER_02: And I would say 85 to 90 percent of them are in the public sector, where a combination of Dolly tagravirate within alfalfa virus and XTC is probably the most preferred combination and is available widely.
- 6:38SPEAKER_01: Wow, thank you so much, Dr.
- 6:39SPEAKER_01: Solomon and Dr.
- 6:41SPEAKER_01: Becker, for giving us that global perspective.
- 6:45SPEAKER_01: This next slide is intended to set context, not to compare our different regions, whether it's better or worse, but the key point here is that regimen choice is shaped by availability, coverage, care, pathways, and infrastructure.
- 7:04SPEAKER_01: For instance, in the United States, treatment available through treatment is available through a mix of private insurance, public programs, uh, a safety net resource, and their barriers is often not simply drug availability, but coverage.
- 7:23SPEAKER_01: Administration, the need for prior authorization or site of care logistics and continuity.
- 7:30SPEAKER_01: With that being said, I'd like to take my first question to Dr.
- 7:34SPEAKER_01: Solomon.
- 7:35SPEAKER_01: Dr.
- 7:36SPEAKER_01: Solomon, can you speak to the India access reality, particularly the difference between public sector TDLD access and broader private sector options?
- 7:51SPEAKER_02: Sure.
- 7:51SPEAKER_02: So I think like I mentioned before, India does have a public sector ART program that was supported by the Indian government that was rolled out in 2004.
- 7:59SPEAKER_02: We have about 700 public sector antiretroviral therapy centers across the country where anyone who goes to that center gets treatment absolutely free, no questions asked.
- 8:09SPEAKER_02: And that's pretty much 85 to 90 percent of all antiretroviral therapy initiation in India.
- 8:16SPEAKER_02: But in the public sector, we do have access to most of the other drugs that are currently available globally, with the exception of long-acting uh antiretrovirals, which will likely change in the next year.
- 8:30SPEAKER_02: So it depends on where patients seek care.
- 8:34SPEAKER_02: If you go to the public sector, you're most likely going to end up with a combination of Tinofare, Lamividine, and Dolitegravir.
- 8:41SPEAKER_02: But if you go to the private sector and you're paying for antiretroviral therapy out of pocket, your horizon of potential options does change.
- 8:53SPEAKER_01: Thank you so much for giving that perspective.
- 8:56SPEAKER_01: Um, I'd like to now turn to Dr.
- 8:58SPEAKER_01: Becker.
- 8:59SPEAKER_01: How should we think about South Africa and the broader southern hemisphere where the WHO recommendations and real-world availability may not match?
- 9:10SPEAKER_04: Yeah, we've certainly seen this kind of thing happening, Christina, throughout the anti-retroviral um history is you know, guidelines sometimes are ahead of availability and sometimes they're actually behind availability.
- 9:24SPEAKER_04: Um in this case, we do see the WHO moving, as I say, cautiously to some populations under certain circumstances, being able to move to two drug oral therapy.
- 9:36SPEAKER_04: So that's still daily.
- 9:37SPEAKER_04: Um, and excitingly, now also, you know, recommending that uh injectable antiretrovirals may be used under certain circumstances.
- 9:47SPEAKER_04: Unfortunately, Rilpiverine, which is the licensed uh cousin of Cabategrava, is not yet uh available in the Southern Hemisphere.
- 9:57SPEAKER_04: But of course, our patients read, uh they go to the internet, they hear about options, um, and I think we're very excited about the fact that options are coming.
- 10:07SPEAKER_04: Um, and that's really what I think we want to discuss because it's so important to ensure that our patients are part of the decision-making uh process.
- 10:17SPEAKER_01: Yes, I really love that you brought up that patient-centered approach.
- 10:21SPEAKER_01: I think that's where all of us are wanting to get to.
- 10:24SPEAKER_01: Um, I'm just hoping that our drug availability is able to catch up.
- 10:29SPEAKER_01: With that being said, I'd like to turn now to Dr.
- 10:32SPEAKER_01: Barber.
- 10:33SPEAKER_01: Can you close this slide with the UK's perspective, particularly how diagnosis, linkage, viral suppression, and service capacity affect eligibility for the long-acting injectable ARTs?
- 10:48SPEAKER_03: In the UK, we have access to Cabotegrave and Real Pivorine for treatment.
- 10:53SPEAKER_03: We have access to Cabotegrave for prevention, but we don't as yet have access to Lena Kapavir for either treatment or prevention.
- 11:00SPEAKER_03: So some slight differences in all of these country settings.
- 11:04SPEAKER_03: We're of course quite lucky in the UK that we have free at the point of access HIV testing and HIV treatment for everyone, regardless of immigration status, uh, regardless of ability to pay.
- 11:17SPEAKER_03: In terms of capacity for long-acting antiretrovirals, we stick at the moment very much to the licensed indications, so these are available as a switch option for people who've already achieved viral suppression on oral treatment.
- 11:32SPEAKER_03: People that want to receive long-acting injectable therapy have to be approved in a multidisciplinary team meeting.
- 11:38SPEAKER_03: I have to say, what very often happens in the UK is because our standard monitoring for people living with HIV is every six months, although people are interested in receiving injectable therapy, when they hear that they have to come in every eight weeks and they're used to coming in twice a year, very often this is a barrier because they feel they have agency and control over their oral tablets at home, and coming in twice a year normalizes their HIV.
- 12:04SPEAKER_03: But for some individuals, of course, there are considerable benefits to injectable therapy.
- 12:10SPEAKER_03: It may free them from stigma or from inadvertent disclosure of their status.
- 12:15SPEAKER_03: And for these people, it can really offer an improvement in their health-related quality of life.
- 12:21SPEAKER_03: So we do offer injectable therapy to people who want it, people who express a desire to have it.
- 12:26SPEAKER_03: The other thing I think we have to consider, and when you look at the implementation studies around injectable therapy, is of course our services have to adapt to provide this treatment.
- 12:35SPEAKER_03: If people are coming in six times a year, requiring a viral load at each visit for the first year, this can have an impact on our pharmacy and our nursing teams in particular.
- 12:46SPEAKER_03: So I think this reminds us that there is no one size fits all approach.
- 12:51SPEAKER_01: Thank you so much.
- 12:52SPEAKER_01: I just I wanted to just uh briefly touch on two things that I heard that were really impactful.
- 12:58SPEAKER_01: One is that you're offering services regardless of immigration status, which is incredible.
- 13:04SPEAKER_01: Um, and two uh is really looking at those additional additional touch points and how that may improve overall care, especially in folks who struggle with either housing or food insecurity.
- 13:18SPEAKER_01: Before we individualize treatment around preference, we need the clinical foundation, HIV RNA, CD4 count, resistance history, hepatitis B viral status, renal and hepatic function, pregnancy status or intention, any comorbidities, and any possible drug-drug interactions.
- 13:43SPEAKER_01: Dr.
- 13:44SPEAKER_01: Barber, what are the clinical factors that should never be missed before initiating, simplifying, or switching someone's antiretroviral therapy?
- 13:55SPEAKER_03: Thank you so much.
- 13:56SPEAKER_03: And I I think you've really covered all of the important points for me already.
- 14:00SPEAKER_03: But if we just dig into a couple of them in a little bit more detail and think about what's really important when we talk to someone about changing antiretroviral therapy, I think some of the challenges at the moment can actually be an antiretroviral history and getting baseline data, including resistance mutations at baseline or historically, because we see people who move countries, we see people who move clinics.
- 14:25SPEAKER_03: Whilst we may know if someone has current active chronic hepatitis B, it may be less easy sometimes to find out whether or not they have historically had uh, for instance, a core antibody that's positive for hepatitis B or to identify clearly what their history is with vaccination.
- 14:42SPEAKER_01: Yes, I could not agree more.
- 14:45SPEAKER_01: Dr.
- 14:45SPEAKER_01: Becker and Dr.
- 14:46SPEAKER_01: Solomon, are there clinical factors that become especially important in your settings because of potential challenges around things like tuberculosis, uh hepatitis, pregnancy considerations, or limited access to those resistance testing or genotypic testing that you discussed earlier?
- 15:07SPEAKER_04: So comorbidities, both with tuberculosis and hip B, are real considerations.
- 15:12SPEAKER_04: Now the HIP B isn't necessarily a stopping point, but tuberculosis both interact.
- 15:19SPEAKER_04: Uh, the the basic um you know keystone uh treatment for uh tuberculosis, as everyone knows, is rifampicin.
- 15:29SPEAKER_04: We do not have easy access to rifabutin, so it is a a strong inducer of the CYP3A system and therefore is not compatible with uh rifampicin, with cabitegrava or with lenacapavir.
- 15:45SPEAKER_04: And so both of those drugs uh need to be, in the case of cabotegrava, we have no data, so they actually need to not be used in that setting.
- 15:54SPEAKER_04: With lena capavir, the requirement is to increase the dose of lena capavir, which is a substrate of CYP3A.
- 16:04SPEAKER_04: And so um this puts a real uh spanner in the works, if you like, when it comes to tuberculosis.
- 16:12SPEAKER_02: Yeah, I don't have much to add to what Lindigail and Tristan have already said, but I think the one key point I want to bring out is like the baseline access to HIV RNA testing and resistance testing.
- 16:22SPEAKER_02: It's almost never done at baseline, right?
- 16:24SPEAKER_02: And so it's it's almost never done the baseline HIV RNA or the baseline resistance test.
- 16:29SPEAKER_02: And I think that's something that can get complicated, especially as cabotegrave rolls out.
- 16:34SPEAKER_02: We have seen from the pivotal phase three trials for um cabotegrave that led to the licensing that all the breakthrough infections did have some, or not all of them, many of them had some resistance to INST, which could complicate access to first line and the efficacy of the first line, because we discussed earlier in sub-Saharan Africa or in Asia, Tinophere, Lamavidine, and olitegrave is your standard first line.
- 17:00SPEAKER_01: Yeah, I agree.
- 17:01SPEAKER_01: And not just that, but also if you're trying to switch to a two-drug regimen, it's much more difficult to do that if you don't have baseline resistance testing.
- 17:10SPEAKER_01: Um, and we definitely don't want patients to fail on their new regimens.
- 17:16SPEAKER_03: And let's bear in mind, if I can just jump in to say you don't have to stay on something forever.
- 17:20SPEAKER_03: So we've got enough options.
- 17:21SPEAKER_03: If something's not working out, you can switch and you can still switch back if you've not developed any new resistance.
- 17:27SPEAKER_03: So I think that's a very important reassurance for individuals who are considering trying something to know that they can always opt to switch back if they're not getting on with it.
- 17:36SPEAKER_04: You know, with tuberculosis, you could come off, as we've done in our CABR or Pivereine uh cohorts, come off for the time that they're on their TB therapy and then shift them back as soon as that TB therapy.
- 17:51SPEAKER_04: So again, none of this is absolute, which is which is really important.
- 17:58SPEAKER_01: So our next slide um is the five-step approach to shared decision making.
- 18:04SPEAKER_01: This is per uh is the practical backbone of the activity.
- 18:08SPEAKER_01: Shared decision making does not mean presenting every possible regimen, it means identifying clinically reasonable options, explaining them plainly, and then asking what will actually fit into the person's life.
- 18:24SPEAKER_01: So um I will start with Dr.
- 18:26SPEAKER_01: Becker.
- 18:27SPEAKER_01: Um, what are some of the uh potential um points that you think of when you think about shared clinical decision making?
- 18:36SPEAKER_04: So the first is, you know, really try and invite that participation.
- 18:41SPEAKER_04: So set up the rapport, make sure that there is a two-way um discussion.
- 18:46SPEAKER_04: I think this needs to be on a level uh where you know the patient and the provider are are equal in seeking the best um option.
- 18:56SPEAKER_04: And there isn't necessarily only one, as Tristan has mentioned.
- 18:59SPEAKER_04: Um, you know, you need to open the possibility that there may be more than one option for this person.
- 19:07SPEAKER_04: And then, of course, you are sitting with the information as the provider.
- 19:11SPEAKER_04: So it is important to be able to actually put in a very frank, transparent, objective way the information in front of people.
- 19:18SPEAKER_04: And it's important to, in a simple and transparent way, make the options available from oral therapy through to injectable to simplification to drug therapy and so on.
- 19:31SPEAKER_04: Now it's then also important to see what is important in this individual in the it at this stage in their life course.
- 19:37SPEAKER_04: Are they contemplating conception?
- 19:40SPEAKER_04: Are they, you know, thinking about traveling a lot in the future?
- 19:44SPEAKER_04: Are they stable in their environment at the moment?
- 19:46SPEAKER_04: Are they just sick of taking daily pills and wanting an option and in danger, therefore, of offloading their treatment altogether?
- 19:55SPEAKER_04: Um, and and it's important again to have that element of trust that somebody feels that they can share that with you, and you're not going to be judgmental in the options.
- 20:05SPEAKER_04: And then that isn't the end of the story.
- 20:08SPEAKER_04: So, you know, you you can start a regimen or get them going and then bring them back in review because maybe maybe this intramuscular injection is more painful than they'd thought.
- 20:21SPEAKER_04: Or maybe they'd heard a lot about nodules, and then actually it isn't so bad after all.
- 20:26SPEAKER_04: Um, or they want to start cautiously and and move on to something a little bit later.
- 20:32SPEAKER_04: So there may be opportunities for shifting um uh further down the line, and that's why evaluation is really important.
- 20:39SPEAKER_04: So a nice kind of assessment of or process that uh we should go through, and that will become more natural as people start to engage.
- 20:49SPEAKER_04: I think the most important advice is really to recognize that this person is the expert of their own lives and they know what um suits them, they need the knowledge and and and the understanding in order to make good decisions, and your role is to guide them towards that good decision.
- 21:10SPEAKER_01: Yeah, I love that so much.
- 21:11SPEAKER_01: Thank you for going over that in such uh fine detail.
- 21:15SPEAKER_01: Um so this slide is intentionally broad.
- 21:19SPEAKER_01: The point is not to cover every population in detail, the goal was a strategy-first approach using selected examples to show how clinical factors, patient priorities, and regional access shape treatment decisions.
- 21:36SPEAKER_01: Um, I'm going to ask this question of the panel.
- 21:39SPEAKER_01: Um, at this point, um, I want to highlight and ask each of you to pick one of the aspects of this beautiful wheel that we have or a clinical context where individualized treatment plans change what you ask, what you offer, or how You follow up with your patient.
- 22:02SPEAKER_01: So I'll go ahead and start with Dr.
- 22:05SPEAKER_01: Barber.
- 22:07SPEAKER_03: Thank you so much.
- 22:08SPEAKER_03: I'm going to center Linda Gale's point about the person being the expert by experience, lived experience, tremendously important for all of us to remember.
- 22:17SPEAKER_03: And I'm going to focus on our area of specialization here at the Royal Free Hospital in London, on older adults thinking about people who are aging with HIV, but not just their birthday age.
- 22:28SPEAKER_03: I think it's also very important we remember their HIV age.
- 22:32SPEAKER_03: And the reason I think that's important is because, of course, you can have acquired HIV perinatally, be just, you know, 30 or 35 on your birthday and have been living with HIV for the same number of years.
- 22:45SPEAKER_03: And that means you've been living with HIV for a long time.
- 22:47SPEAKER_03: But we do know that older adults with HIV are more likely to take an increasing number of other medicines for other comorbidities that they may acquire either at an earlier age or with greater severity.
- 23:00SPEAKER_03: And as people get older, of course, they can process and metabolize drugs in a different way.
- 23:04SPEAKER_03: And also we need to get confident, even if it's not our role as HIV specialists, but to engage with our other colleagues to de-prescribe medicines that may be causing more problems than they are causing benefits.
- 23:17SPEAKER_03: And of course, certain drugs, as people get older, certain classes of drugs may lead to, for instance, an increased risk of falls or more dizziness or more sleep disturbance.
- 23:28SPEAKER_01: I really love the fact that you brought up the difference between chronologic age and biological age, because some of our patients, um, you know, they they are their biological age does not match their chronologic age.
- 23:41SPEAKER_01: And so I think that's a a wonderful thing to emphasize, especially for our long-term thrivers who've been um living with a positive status for many years.
- 23:51SPEAKER_01: Uh, Dr.
- 23:52SPEAKER_01: Becker?
- 23:54SPEAKER_04: Christine, anybody who knows me will know that I'm passionate about adolescence and young people.
- 23:58SPEAKER_04: And so that's across the board.
- 24:00SPEAKER_04: Doesn't matter whether you're an African young woman or you are from a key pop, as we as we sort of sometimes think about people who are very vulnerable to HIV but don't have good access to services.
- 24:12SPEAKER_04: Younger people are living very busy lives.
- 24:15SPEAKER_04: They have many, many priorities, and taking a pill a day often falls off that list of priorities.
- 24:20SPEAKER_04: Doesn't matter whether they've been living with HIV since they were born or whether they've recently acquired it as a young person, they also are acutely aware of stigma.
- 24:31SPEAKER_04: So they are, you know, this is a time in their lives where they're very affected by peers and normal normality.
- 24:40SPEAKER_04: Um, and I put that in inverted commas because what they so yearn is to just look like everybody else.
- 24:47SPEAKER_04: And so often the rattling bottle of pulls, particularly when we give them multi-month dispensing, you know, to make sure they're not clogging up our clinic.
- 24:55SPEAKER_04: So they're given three or six months of treatment.
- 24:58SPEAKER_04: This is not what they want.
- 24:59SPEAKER_04: They want to walk away from the clinic and feel like, you know, they're they are free and they are free of any uh something pulling them down.
- 25:10SPEAKER_04: Um and so this population, I think, really, really loves the idea of an injectable where they don't have to walk away with any kind of pharmacological um tools.
- 25:23SPEAKER_04: Um and they love the idea that they only have to come back every two months or every six months, um, as the case may be for an uh a renewed injection.
- 25:33SPEAKER_04: And you know, a little bit of pain once every two months or once every six months is something they're quite willing to put up with as long as they are free of their pills.
- 25:42SPEAKER_04: And you know, and the feedback I've got from adolescents is I feel free at last.
- 25:46SPEAKER_04: I I can forget about HIV when I'm I'm not here.
- 25:49SPEAKER_04: And and this is really critical.
- 25:51SPEAKER_04: For the first time, we're seeing these cohorts of young people virally suppressed.
- 25:57SPEAKER_04: Uh, and it's just hugely exciting.
- 25:59SPEAKER_04: So I think it's a terrific time for us to really think about um getting these drugs into particularly young people.
- 26:08SPEAKER_01: Thank you so much.
- 26:09SPEAKER_01: Uh, Dr.
- 26:10SPEAKER_01: Solomon, I would love to hear your perspective on uh managing some of our patients who may have other comorbidities or um, you know, lived experiences that may be challenging around access to antiretrovirals.
- 26:25SPEAKER_02: So I think I'm gonna focus primarily on people who use drugs because that's a population that's commonly overlooked.
- 26:31SPEAKER_02: And we never really ask questions about substance use.
- 26:34SPEAKER_02: Do you actually inject drugs?
- 26:36SPEAKER_02: Do you use drugs?
- 26:37SPEAKER_02: Do you use methamphetamines?
- 26:38SPEAKER_02: So it is important.
- 26:40SPEAKER_02: And when you're looking at people who inject drugs, I think a lot of them get on harm reduction services.
- 26:45SPEAKER_02: They may be on methadone or buprenorphine, but at the same time, you may also have another person who injects drugs who's unstably housed, living on the streets, will not have access to store their medications.
- 26:57SPEAKER_02: And this is something that we've heard very commonly all the way from Bangar in Maine to uh New Delhi in India, where a lot of them lose their overall medications when they're on the streets.
- 27:08SPEAKER_02: And so in the US, they're actually trying to switch these people to long-acting injectables so that way they don't have to worry about where they store their medications.
- 27:17SPEAKER_02: Asking and getting ahead of it will definitely help you individualize that regimen and really makes that person in front of you feel heard and respected because you really are considering their entire social concept context in the selection of their appropriate anti-retroviral regimen.
- 27:36SPEAKER_01: Wonderful.
- 27:37SPEAKER_01: We're gonna go ahead and move on to the next slide.
- 27:40SPEAKER_01: So once clinical eligibility is established, preferences matter because the best regimen is the one the patient can obtain, accept, and sustain.
- 27:51SPEAKER_01: Um, in this instance, I always say medications don't work unless you're able to take them.
- 27:58SPEAKER_01: So a few of the things that I personally talk about is pill burden and dosing frequency.
- 28:06SPEAKER_01: I would also add pill size.
- 28:09SPEAKER_01: Um, some of our newer products that are coming out, um, they are taking into consideration pill size and people's ability to swallow pills.
- 28:19SPEAKER_01: Um, I think that also brings into consideration the tolerability of the regimen, um, their ability to maintain privacy.
- 28:28SPEAKER_01: Um, those are things that are our consideration for whether or not someone will accept and sustain their regimen, as well as access and cost.
- 28:38SPEAKER_01: Um, the formulation preference.
- 28:40SPEAKER_01: So I'm going to now turn to Dr.
- 28:42SPEAKER_01: Solomon.
- 28:43SPEAKER_01: If you could talk to us a little bit about asking around hormone therapy therapy, especially in our individuals of trans experience who are undergoing gender-affirming care.
- 28:56SPEAKER_01: Can you speak to why that matters so much, especially when we talk about adherence to antiretroviral therapy, as well as how we establish trust in this particular patient population?
- 29:07SPEAKER_02: No, sure.
- 29:08SPEAKER_02: I think the most important thing that we very often tend to forget is getting them on antiretroviral therapy is our priority, but their priorities may be different from our priorities, right?
- 29:19SPEAKER_02: For many of the people in the trans community, the trans people, it really is that gender-affirming care and making sure their gender identity matches what they want it to look like.
- 29:28SPEAKER_02: And so anything that they see as a risk to that happening can impact adherence.
- 29:35SPEAKER_02: So I think a very common misconception is if antiretroviral therapies may interact with hormone replacement therapy, so their gender affirming care is going to be impacted.
- 29:45SPEAKER_02: But there are some data available, so just presenting the data and saying this is what has been done.
- 29:50SPEAKER_02: And you can see that there's no impact on your hormone replacement therapy.
- 29:54SPEAKER_02: So taking antiretroviral therapy is actually going to be beneficial to you without impacting your gender affirming care really helps um establish that rapport with the community that you have talked to them.
- 30:06SPEAKER_02: So they're maybe offering subcutaneous injections or having that conversation with them.
- 30:11SPEAKER_02: Like, is it really going to be a problem or is it not?
- 30:14SPEAKER_01: Yeah, I couldn't agree more.
- 30:16SPEAKER_01: I would also state as well as where they're at within their transition also can impact um whether or not they choose to take a certain antiretroviral regimen, whether that's their beginning of their journey of transitioning to the other gender versus someone who has been longstanding and been on gender-affirming care for a long period of time.
- 30:39SPEAKER_01: Dr.
- 30:39SPEAKER_01: Barber, can you talk a little bit more about how you make the decision to switch patients or why you may want to switch a patient to a different regimen?
- 30:50SPEAKER_03: We've talked about thinking about side effects of existing regimens, drug-drug interactions, pregnancy intention, pill burden and size, differential access in different country settings, and so on.
- 31:01SPEAKER_03: But I do actually think the key here is to think about individual preference.
- 31:06SPEAKER_03: Now, I appreciate this is talking as someone who's in an area of privilege in terms of having access to anti-retroviral options.
- 31:14SPEAKER_03: But even so, I think in all settings we really need to understand, as we've mentioned before, what is important to the individual that's in front of us, what's going to work best in their life, because this is treatment you are taking for life, to achieve viral suppression, to have normal life expectancy, to hopefully have very good health-related quality of life.
- 31:33SPEAKER_03: And I guess my main take-home when thinking about offering simplification or switch options is to have a non-judgmental, non-paternalistic and holistic approach.
- 31:47SPEAKER_03: Because I've been really surprised.
- 31:49SPEAKER_03: I've made assumptions about people I've known for a long time and thought, you know, they won't want injectable anti-reach virals, they've got a busy job, they're probably very happy coming in every six months with their single tablet regimen.
- 32:01SPEAKER_03: And then I've described injectable therapy to them and their eyes have lit up, and it's they've often revealed something to me that they may not have disclosed in the past about why injectables would be very important to them.
- 32:13SPEAKER_04: Yes.
- 32:14SPEAKER_04: Yeah, and Tristan, I think probably the one population I'd I'd be a little bit nervous about, and and and I think often guidelines go down this road, is the what is the person who is already pregnant and is virally suppressed.
- 32:29SPEAKER_04: And this is why we rarely want to have a discussion with them pre-conception.
- 32:33SPEAKER_04: You know, what are you thinking?
- 32:35SPEAKER_04: One, because you may have side effects that, you know, all antivirals have side effects, right?
- 32:41SPEAKER_04: Now, obviously, if they're struggling with their viral suppression, you may need to intervene with a with a shared decision around what is a better treatment here for you.
- 32:53SPEAKER_04: And then that becomes a situation.
- 32:55SPEAKER_04: But I, you know, I would just caution around um maintaining stability in in the setting of those nine months and shortly after birth.
- 33:06SPEAKER_03: Yeah, I completely agree with you.
- 33:07SPEAKER_03: And I think, you know, one of the upsetting things is when we look to offer someone a new treatment or they've heard about a new treatment, they come in asking for information, and they've got something that limits their ability to access that.
- 33:19SPEAKER_03: So that would include, for instance, someone with hepatitis B coinfection.
- 33:23SPEAKER_03: For me, I had someone who really wanted to get injectable antiretroviral therapy, uh, who'd acquired HIV through sexual assault, who found the daily reminder of taking tablets was very triggering.
- 33:34SPEAKER_03: Uh, and unfortunately, he had an NNRTI mutation that meant he couldn't receive injectable cabotagravir and rhylpivrine.
- 33:42SPEAKER_01: Yeah, I just also wanted to just briefly um touch on the point, and and Dr.
- 33:47SPEAKER_01: Solomon, you can address this.
- 33:49SPEAKER_01: Is where do you draw the line between simplification and wanting to protect future regimens or preserve the ability to use um regimens in the future um because of you know different drug classes that are being used?
- 34:04SPEAKER_02: Yeah, that's I guess a very challenging question and depends on your setting, right?
- 34:09SPEAKER_02: So in a setting like in the like the US or UK or some or other countries, but you have access to resistance testing, you have access to uh viral loads at baseline, you have access to like everything that you would need to make those decisions, multiple regimens, you could try and push the line a little bit more towards simplifying treatment and not really worrying about protecting future options because your future options are limitless, and you could sort of select regimens one after the other after the other.
- 34:38SPEAKER_02: So I actually think one tablet once a day is not that bad.
- 34:43SPEAKER_02: So depending on where you are, it depends on how you want to draw that line and who the person is sitting across from you.
- 34:50SPEAKER_02: I would probably say on the side of caution and try to protect your future options and keep people on simple regimens at as we are right now.
- 34:59SPEAKER_04: So giving multi-month dispensing, um, making sure, you know, here in South Africa, you could get it in a package, uh, you know, couriered package uh to your home, um, which clearly, you know, hugely simplifies.
- 35:14SPEAKER_04: We have these things called adherence clubs where an individual could fetch their treatment for other members.
- 35:20SPEAKER_04: So there may be other things you can think about around simplification.
- 35:24SPEAKER_04: And Sunil, I know you know that this also happens in India.
- 35:28SPEAKER_04: So, you know, that that that may be another discussion to be having.
- 35:32SPEAKER_01: All right, our next slide.
- 35:34SPEAKER_01: What about the persons living with HIV's perspective?
- 35:38SPEAKER_01: So these slides remind us that viral suppression is necessary, but not the whole story.
- 35:44SPEAKER_01: People living with HIV often prioritize fewer medications, fewer reminders of HIV, fewer long-term toxicities, and better quality of life.
- 35:54SPEAKER_01: Uh, Dr.
- 35:55SPEAKER_01: Barber, would you like to add anything else to this slide as far as just perspectives that you have seen with your patient population?
- 36:05SPEAKER_03: You know, asking people here that are stable uh on what we assume to be well-tolerated treatments, we see that nearly two-thirds were worried about the long-term side effects of HIV medicines.
- 36:16SPEAKER_03: Uh, and about 75% were willing to switch to a regimen with fewer antiretroviral agents, provided they stay undetectable.
- 36:24SPEAKER_03: And one of the three top reasons to switch regimens was reducing the number of medicines.
- 36:28SPEAKER_03: So I think it really reminds us we need to ask people with HIV what's important to them and what their priorities are.
- 36:36SPEAKER_01: Yeah, so let's move on to the next slide, which is really talking about uh quality of life and this concept of having the fourth 90.
- 36:46SPEAKER_01: Um, could you expand on this a little further?
- 36:49SPEAKER_03: This slide includes my terrible drawing, so apologies.
- 36:52SPEAKER_03: But I think what I was trying to say here was that I don't like thinking about the fourth 90 as a diminutive uh 90.
- 37:00SPEAKER_03: The UK has strong viral suppression outcomes, but the fourth 95 asks whether people are well, not just suppressed, and reminds us, I think, that treatment conversations should include wellness, comorbidities, self-management capacity, and quality of life.
- 37:16SPEAKER_03: And we know that treatment success includes what the individual experiences day to day.
- 37:24SPEAKER_01: Wonderful.
- 37:25SPEAKER_01: So the next uh slide talks about counseling on dosing frequency and matching someone's antiretroviral therapy to their daily lifestyle.
- 37:35SPEAKER_01: Um daily oral and long-acting options require different adherence support.
- 37:40SPEAKER_01: The question is not just which regimen works, but which regimen works for this person in this care model.
- 37:48SPEAKER_01: Would you like to add any um comments to this or uh, you know, give us any insights um around how you um help people to match their ART with their lifestyle?
- 38:01SPEAKER_04: Yeah, so Christine, I like to think of this as there's the biomedical intervention, which is the pulls or the injection, the treatment, and then there's the there's the patient.
- 38:11SPEAKER_04: And we put the patient in the middle, the patient-centered, they then need to understand what goes with the this regimen in the health system that I need to understand.
- 38:21SPEAKER_04: So, pulls, I've already spoken about adherence clubs, multi-month dispensing.
- 38:24SPEAKER_04: It might mean they don't have to come back to the clinic for up to six months at a time, you know.
- 38:29SPEAKER_04: On the other hand, I with the injection, I get the freedom of throwing away my pills, as it were, but now I have to come to the clinic on time at a specific time within a specific window.
- 38:42SPEAKER_04: Um, you know, I might have a drug-drug interaction for a period of time, and then I have to go on to something else for, as we've spoken about, TB therapy.
- 38:52SPEAKER_04: So this is really important to get into the patient's mind.
- 38:56SPEAKER_04: Here you are, but there is this kind of what I call three-dimensional treatment, um, which takes into consideration the setting, the model, the regimen, and of course the patient and their preference.
- 39:10SPEAKER_04: And all of those are quite dynamic and need to be considered and brought to the fore.
- 39:15SPEAKER_01: We're going to move on to a case presentation, uh, specifically a case around highly treatment experienced HIV.
- 39:24SPEAKER_01: So let's apply what we've learned.
- 39:27SPEAKER_01: This is a 52-year-old male with multidrug-resistant HIV who has had virologic failure despite adherence support.
- 39:35SPEAKER_01: Resistance testing shows limited fully active options, and he wants to reduce his daily pill burden if clinically appropriate.
- 39:43SPEAKER_01: Which of these approaches do you think would be most appropriate?
- 40:04SPEAKER_01: So, in this instance, the best answer is option B.
- 40:09SPEAKER_01: The use of linicaphair as part of an optimized background regimen guided by resistance history and expert consultation.
- 40:17SPEAKER_01: The key point here is that linicapitare is not used as a standalone fix.
- 40:22SPEAKER_01: It must be paired with optimized regimens.
- 40:25SPEAKER_01: Capitagavir and repeverine is not appropriate here because this patient has had virologic failure and suspected or known resistance concerns.
- 40:36SPEAKER_01: Can you maybe comment on um why maybe the cabote repeverine um could potentially be an option in maybe some different scenarios based off of this particular case?
- 40:49SPEAKER_04: Yeah, I think we'd want to be a little bit careful with the uh cabotegroviral rulpiverine.
- 40:55SPEAKER_04: Um, as we know, this is a two-dip drug regimen, and one rapiverine is a non-nucleoside reverse transcriptase inhibitor.
- 41:04SPEAKER_04: So we want to be really careful that we are not going to be exposing uh the individual to just one uh one clean drug, as it were.
- 41:12SPEAKER_04: So I think uh we probably would not um go down the road of uh two drugs here, but we would, you know, maybe consider something like N kapavir, a new agent with a very unique resistance profile, and then making sure that there is an optimized background uh to go with that lena capavir.
- 41:34SPEAKER_04: Thank you so much for that perspective.
- 41:37SPEAKER_01: So global strategies for expert consultation in complex antiretroviral decisions.
- 41:43SPEAKER_01: This slide turns the case into a practical pathway.
- 41:46SPEAKER_01: Expert consultation is most helpful when the clinical decision is not straightforward.
- 41:52SPEAKER_01: Resistance history may be incomplete, genotyping may not be available, there have been multiple regimen failures or access constraints limiting ideal options.
- 42:02SPEAKER_01: So for this one, Dr.
- 42:04SPEAKER_01: Barber, can you briefly describe the UK's virtual referral MDT model and how smaller centers can access expertise?
- 42:15SPEAKER_03: This is a really important question for us in the UK at the moment.
- 42:18SPEAKER_03: So thank you so much for it.
- 42:20SPEAKER_03: And this is to discuss particularly complex or expensive regimens and also individuals with a lot of antiretroviral resistance.
- 42:28SPEAKER_03: Some smaller centers may struggle to have a multidisciplinary team of that size.
- 42:32SPEAKER_03: So we encourage people in the UK to work in clinical networks, regional networks, so they can access this specialist advice.
- 42:40SPEAKER_03: But as the amount of resistance and complexity we see starts to fall a little bit, uh it's getting harder and harder sometimes for smaller centers to access that advice.
- 42:49SPEAKER_03: So we're looking at more of a national model now to be able to support people with the most complex individuals living with HIV.
- 42:58SPEAKER_02: Sure.
- 42:58SPEAKER_02: So, like I mentioned, about 90% of people in India receive antiretroviral therapy from the public sector.
- 43:04SPEAKER_02: And so they actually have a special committee in each of the states.
- 43:07SPEAKER_02: It's called the State AIDS Control Expert Panel or SACEP.
- 43:10SPEAKER_02: And if you're still failing based on virologic uh failure and HIV RNA being detectable, then they do a resistance test looking at all your background regimens.
- 43:20SPEAKER_02: Because, like I said, you do have limited options within the government.
- 43:23SPEAKER_02: You have someone with a history of like failing at least two regimens.
- 43:27SPEAKER_02: So this committee comes together, looks at what the history of this person is, what antiretroviral therapy regimens they were exposed to, and then what may be the ideal fit for this person based on what's available in the in the public sector in India.
- 43:43SPEAKER_01: Wonderful.
- 43:44SPEAKER_01: Dr.
- 43:44SPEAKER_01: Becker, in settings where genotyping may not be routine, how do clinicians distinguish non adherence from resistance and decide when to escalate?
- 43:55SPEAKER_04: Well, that's right.
- 43:56SPEAKER_04: I mean, we we need to be careful as well, not to what we say blow up.
- 44:00SPEAKER_04: Options in moving someone too quickly to second line or even to third line if they haven't, in fact, incurred resistance.
- 44:08SPEAKER_04: The most common reason for people having unsuppressed viral load is that they just have, for multiple reasons, not been able to adhere to their medication in a regular way.
- 44:21SPEAKER_04: So it is important to check that out.
- 44:23SPEAKER_04: So, you know, you bring the peers in, you sit people down, you really try and understand why perhaps they're struggling, try and um find ways, tools for people to remember if it's a forgetfulness thing or if they've got a lifestyle difficulty.
- 44:39SPEAKER_04: Can you, you know, modify the regimen they're on or the treatment, how they get their treatment to try and improve things.
- 44:46SPEAKER_04: But otherwise, this is a good time to phone a friend or phone a specialist and get some help.
- 44:52SPEAKER_01: Wonderful.
- 44:52SPEAKER_01: That's what I do.
- 44:53SPEAKER_01: I work for the National Clinician Consultation Center here in the United States.
- 44:57SPEAKER_01: So I am the McCullan expert.
- 44:59SPEAKER_01: So I really appreciate that mentioned.
- 45:02SPEAKER_01: Yes, we're we consider ourselves the original phone a friend.
- 45:06SPEAKER_01: I'm gonna ask you a little bit about the next slide, which is cultural considerations and patient-centered communication.
- 45:13SPEAKER_01: So clinical fit is sometimes not enough, but cultural fit determines whether patients understand, trust, and can act on the treatment plan.
- 45:25SPEAKER_01: Can you uh give us a little bit of insight on how you incorporate those cultural considerations into your patient-centered communications, Dr.
- 45:35SPEAKER_01: Barber?
- 45:37SPEAKER_03: I think there are two things that are really important.
- 45:39SPEAKER_03: So one is to speak to people in their own language, hopefully using professional interpreters, whether that's in person or whether that's telephone-based.
- 45:47SPEAKER_03: I think that's really important, particularly at the time of a new HIV diagnosis.
- 45:53SPEAKER_03: The other thing for us that's tremendously important is to use peer support workers.
- 45:57SPEAKER_03: Again, at the beginning, I think this can be very reassuring.
- 46:00SPEAKER_03: Admittedly, not for everyone.
- 46:02SPEAKER_03: Some people may fear stigma from their own community, for instance.
- 46:05SPEAKER_03: So again, you need to individualize that offer of peer support.
- 46:09SPEAKER_03: But I think having someone who can offer practical advice and use language that someone can understand who has lived experience of HIV can be really important and reassuring for people.
- 46:20SPEAKER_04: Yeah, well, I like what Tristan's already raised.
- 46:22SPEAKER_04: I think it is important to think about language.
- 46:24SPEAKER_04: In my country, there are 11 official languages.
- 46:28SPEAKER_04: So you do want to exactly so you do want wherever possible to see if you can bring in a professional interpreter or even a friend or somebody who, if language is a barrier, where you can have that conversation with somebody.
- 46:42SPEAKER_04: And then particularly with adolescents, peers can be unbelievably powerful.
- 46:48SPEAKER_04: Um so that peer navigator, that other professional who is seen to be more at a level, maybe is themselves using antiretrovirals, and so can identify and have that empathic approach.
- 47:00SPEAKER_04: These are the ways that I certainly use to um, you know, to try and get on on a cultural level with somebody that I'm interacting with.
- 47:11SPEAKER_01: Wonderful.
- 47:12SPEAKER_01: Uh, Dr.
- 47:13SPEAKER_01: Solomon, uh, could you provide uh just one practical communication strategy that you use to make antiretroviral conversations more culturally responsive?
- 47:24SPEAKER_02: So I when I talk to patients, I always try to think about if I was the patient, how would I want to be doctor?
- 47:30SPEAKER_02: Like what is the language?
- 47:32SPEAKER_02: What would I, what information would I want?
- 47:34SPEAKER_02: So really thinking of the person across from you as someone like you and picking the appropriate language, whether it's one of the 11 South African languages or the 22 Indian languages, just making sure that you're communicating in a way that the person across from you understands you, feels heard, feels respected, uh, and there's a lot of dignity in the communication.
- 47:55SPEAKER_02: I think that's really important because more than the anti-retroviral therapies, it's that trust and that rapport you build with the patient where they believe that you're doing this for their best interest.
- 48:06SPEAKER_02: That's what's going to really define your clinical outcomes.
- 48:10SPEAKER_01: Wonderful.
- 48:10SPEAKER_01: Yeah, thank you so much.
- 48:12SPEAKER_01: Now we're gonna turn to the audience response.
- 48:15SPEAKER_01: We'd like to hear from you.
- 48:17SPEAKER_01: In your setting, which barrier most often limits use of long-acting injectable HIV treatment?
- 48:43SPEAKER_01: Patient perspectives, the power of shared decision making in HIV care.
- 48:49SPEAKER_01: We need to tap into the insights of people who are at the center of care.
- 48:54SPEAKER_01: We are pleased to share the insights of our patients' perspective.
- 49:00SPEAKER_00: So my name is Angelina Namiba, and I wear many hats.
- 49:03SPEAKER_00: Uh, but uh as a snapshot, uh, I'm a woman living with HIV, diagnosed over 30 years ago.
- 49:09SPEAKER_00: But I'm also a founder member of a small charity called Um the Forum Network.
- 49:12SPEAKER_00: 4M stands for My Health, My Choice, My Child, My Life.
- 49:17SPEAKER_00: It's a perinatal paymentary project working with mentor mothers living with HIV, where we train, skill, and mentor them up to support their peers going through the pregnancy journey, but also for their own personal development.
- 49:29SPEAKER_00: So I believe that, you know, the concept of my health, my choice, my life is at the core of shared decision making because, you know, it does quite a number of things.
- 49:40SPEAKER_00: You know, it it enables us to adhere to our treatment, um, it shifts the power dynamic between the healthcare provider and the patients because we are we're actually being involved rather than being told what to do.
- 49:53SPEAKER_00: We're involved in the decision making.
- 49:55SPEAKER_00: Um, but it can also have the potential to dismantle those clinical barriers whereby, you know, uh our clinicians believe in us and we believe in our clinicians, and we can actually have a bi-directional conversation about our choices and our treatments.
- 50:10SPEAKER_00: And it can also reduce stigma through the the way we change the language that we use.
- 50:15SPEAKER_00: Um, so it also has the potential to reduce that stigma.
- 50:18SPEAKER_00: Uh so you know, it can do quite a lot of things.
- 50:21SPEAKER_02: The one thing we should never forget is like regardless of what the size of the team is, the patient is always in the center.
- 50:29SPEAKER_02: And the decision always has to involve the patient.
- 50:32SPEAKER_02: And I think that is really the most critical component of shared decision making.
- 50:38SPEAKER_04: Yeah, and maybe I'll just add that I think shared decision making means a very flat kind of structure.
- 50:44SPEAKER_04: It isn't hierarchical, there isn't somebody who has more power than somebody else.
- 50:48SPEAKER_04: And it was always very humbling for me when we first started to task shift and task share to lay counselors and to peer navigators and what we call the adherence counselors, many of them living with HIV themselves.
- 51:02SPEAKER_04: When our patients started to say, No, I don't want to talk to you, I want to talk to that person.
- 51:06SPEAKER_04: They know more and they understand me better.
- 51:08SPEAKER_04: And that was then a recognition that absolutely every team member had a role and was very important.
- 51:15SPEAKER_04: And I cannot agree more with Sunil, we've got to keep the patient in the middle of that flat structure of shared decision making.
- 51:26SPEAKER_01: These clinical point tools are available through the activity and the CME Outfitter Infectious Disease Hub.
- 51:33SPEAKER_01: Let's summarize with our SMART goals specific, measurable, attainable, relevant, and timely.
- 51:42SPEAKER_01: That is what we hope that our audience will take from this presentation to apply to your practice.
- 51:49SPEAKER_01: To close, here are three practical goals we hope learners can take back to their practices.
- 51:55SPEAKER_01: Ask what my health, my choice, my life means for each patient.
- 52:01SPEAKER_01: Match anti-retroviral selection or switching to both clinical eligibility and world-world visibility and using cultural responsive shared decisions making to select a regimen that patients can obtain, accept, and most importantly, sustain.
- 52:21SPEAKER_01: Please be sure to check out the additional resources located on the CME Outfitter website.
- 52:28SPEAKER_01: Visit the CME Outfitters Infectious Disease Hub for both healthcare professionals and patients.
- 52:36SPEAKER_01: This CMEO snack is one of a four-part series.
- 52:40SPEAKER_01: We hope that you'll check out the other short and focused activities.
- 52:46SPEAKER_01: To receive credit for today's program, complete the post-test and evaluation, and you will be able to download and print your certificate immediately upon completion.
- 52:56SPEAKER_01: We would like to thank you again for participating in today's activity.
- 53:01SPEAKER_01: And to the faculty, thank you again for joining me today.
- 53:05SPEAKER_01: And thank you to our audience for participating and providing the best care for patients living with HIV.